October 26, 2022 01:55 PM EDT
Pharma
Law

Vi­a­tris and oth­ers be­come lat­est tar­gets of No­var­tis' En­tresto patent lit­i­ga­tion

Nicole DeFeudis

Editor

No­var­tis pro­tects its block­busters like a bear and her cubs, re­cent­ly tak­ing a Gilenya patent bat­tle all the way to the Supreme Court. Now it� …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA de­lays PDU­FA date for small biotech, rais­ing ques­tions about im­pact of agency cuts

Pfiz­er launch­es a new wave of cost cuts, ex­pects $7.7B in to­tal sav­ings through 2027

As­traZeneca, No­var­tis ex­e­cute ‘US for US’ strat­e­gy as phar­ma tar­iffs near

As­traZeneca posts an­oth­er Truqap study fail, says Chi­na im­port tax could triple

FDA ap­proves Abeona’s skin dis­ease cell ther­a­py

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times